ZNTLZentalis Pharmaceuticals, Inc.

ZNTL Stock Price, Valuation & Chart | Zentalis Pharmaceuticals, Inc.

Compare

$3.770+0.06 (+1.62%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ZNTL intrinsic value ZNTL calculated fair value vs price

Overview Financials Dividends Ratios

ZNTL Historical price chart

ZNTL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization268.37M

PE Ratio-1.93

EPS-1.95

Trading Volume897.77K

Today's High/Low3.88/3.69

Dividend Yield0.00

52 Week High/Low6.95/1.21

Shares Outstanding71.19M

ZNTL Financial Statement

ZNTL Analyst ratings

ZNTL Analysis & performance metrics

ZNTL Company profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various…

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the…

ZNTL Management team

Name

Position

Andrea Paul J.D.

Chief Legal Officer & Corporate Secretary

Ingmar Bruns M.D., Ph.D.

Chief Medical Officer

Julie M. Eastland M.B.A.CEO

Chief Executive Officer, President & Director

Haibo Wang

Chief Business Officer

Vincent A. Vultaggio

SVice President of Finance & Principal Accounting Officer

Kimberly Freeman

Chief Strategy Officer

Wendy Chang

Chief People Officer

Name

Position

Andrea Paul J.D.

Chief Legal Officer & Corporate Secretary

Ingmar Bruns M.D., Ph.D.

Chief Medical Officer

Julie M. Eastland M.B.A.CEO

Chief Executive Officer, President & Director

Haibo Wang

Chief Business Officer

Vincent A. Vultaggio

SVice President of Finance & Principal Accounting Officer

Kimberly Freeman

Chief Strategy Officer

Wendy Chang

Chief People Officer

Management Team

Andrea Paul J.D.

Chief Legal Officer & Corporate Secretary

Ingmar Bruns M.D., Ph.D.

Chief Medical Officer

Julie M. Eastland M.B.A.CEO

Chief Executive Officer, President & Director

Haibo Wang

Chief Business Officer

Vincent A. Vultaggio

SVice President of Finance & Principal Accounting Officer

Kimberly Freeman

Chief Strategy Officer

Wendy Chang

Chief People Officer

Management

Andrea Paul J.D.

Chief Legal Officer & Corporate Secretary

Ingmar Bruns M.D., Ph.D.

Chief Medical Officer

Julie M. Eastland M.B.A.CEO

Chief Executive Officer, President & Director

Haibo Wang

Chief Business Officer

Vincent A. Vultaggio

SVice President of Finance & Principal Accounting Officer

Kimberly Freeman

Chief Strategy Officer

Wendy Chang

Chief People Officer

Total 7 executives

ZNTL Frequently asked questions

What is Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Price?

Current stock price of Zentalis Pharmaceuticals, Inc. (ZNTL) stock is $3.770. The stock price is +1.62% higher in the session. The intraday range can be seen from this page. Volume of Zentalis Pharmaceuticals, Inc. (ZNTL) stock is 897.77K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Zentalis Pharmaceuticals, Inc. (ZNTL) stock price going up or down today?

The stock price of Zentalis Pharmaceuticals, Inc. (ZNTL) can change with earnings, company news, and overall market sentiment. Zentalis Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Zentalis Pharmaceuticals, Inc. stock expensive at its current price?

Whether Zentalis Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ZNTL on this page is -1.93. EPS on this page is -1.95. Compare those figures with peers and growth expectations before deciding if the current Zentalis Pharmaceuticals, Inc. price is justified.

How has the stock price of Zentalis Pharmaceuticals, Inc. (ZNTL) performed historically?

Historical performance for Zentalis Pharmaceuticals, Inc. (ZNTL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ZNTL reacted to past earnings and market events.

Should I buy Zentalis Pharmaceuticals, Inc. (ZNTL) stock, at this price?

Buying Zentalis Pharmaceuticals, Inc. (ZNTL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.